Fagron

Fagron Intangible Assets

The Intangible Assets of Fagron (FAGR.BR) as of Nov 1, 2026 is 99.67 M EUR. In the previous year, Intangible Assets was 61.40 M EUR — a change of 62.34% (higher).

Intangible Assets

99.67 MEUR

YoY

62.34%

Last updated:

Intangible Assets of Fagron is 2025 99.67 M EUR. Intangible Assets of Fagron was 2024 61.40 M EUR. It decreases by 62.34% higher compared to the previous year.

The Fagron Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
26.25 M EUR
Jan 1, 2019
28.81 M EUR
Jan 1, 2020
24.51 M EUR
Jan 1, 2021
30.67 M EUR
Jan 1, 2022
33.63 M EUR
Jan 1, 2023
48.56 M EUR
Jan 1, 2024
61.40 M EUR
Jan 1, 2025
99.67 M EUR
The Fagron Intangible Assets history
YEARIntangible AssetsYoY
99.67 MEUR+62.34%
61.40 MEUR+26.43%
48.56 MEUR+44.38%
33.63 MEUR+9.68%
30.67 MEUR+25.10%
24.51 MEUR-14.92%
28.81 MEUR+9.74%
26.25 MEUR+21.22%
21.66 MEUR-23.26%
28.22 MEUR-23.71%
36.99 MEUR-30.44%
53.18 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fagron Stock analysis

What does Fagron do? Fagron NV is an internationally operating company that focuses on the development and production of customized medications for pharmacies and hospitals. The company was founded in 1990 in Rotterdam, Netherlands. The beginnings of Fagron NV were in the Netherlands, where the company was established as Roterodamum Chemie BV. In the late 1990s, the company was converted into a holding company called Arseus NV, which later received the name Fagron. In 2012, Fagron was listed on the Euronext stock exchange in Brussels. Fagron operates globally and has locations in Europe, North America, Latin America, the United Arab Emirates, Asia, and Australia. Fagron's business model is based on the production of specialized medications for individual patient needs. The company offers a wide range of pharmaceutical active ingredients, raw materials, and processing services. There is also the possibility to develop and manufacture customized formulations tailored to the needs of patients. Fagron not only manufactures customized medications but also provides training and support for pharmacies and hospitals. Fagron operates in three main divisions: Specialty Pharma (hospital care), Community Pharma (prescription and non-prescription medications), and Compounding Services (custom formulations). The Specialty Pharma division specializes in medications for use in hospitals. It offers a wide range of products that can be used in the treatment of conditions such as cancer, HIV, and tuberculosis. These medications are manufactured in various dosage forms, such as injections, infusions, and tablets. The Community Pharma division focuses on prescription and non-prescription medications. Both branded and generic medications are offered. These are delivered directly to pharmacies, hospitals, and clinics. The Compounding Services division specializes in the production of customized medications. Fagron works closely with pharmacies and hospitals to meet individual needs. This includes, for example, the manufacture of medications in specific dosages or the combination of several active ingredients in a custom formulation. Fagron offers a wide range of products, including hormones, pain medications, cancer drugs, medications for the treatment of skin diseases, ophthalmic products, and anti-infectives. Pharmaceutical active ingredients and raw materials are also offered. Overall, Fagron is a global leader in the production of customized medications. It has extensive experience and expertise in the manufacturing of pharmaceutical formulations and offers a wide range of products and services. The various divisions of Fagron allow the company to meet the diverse needs of its customers and maintain its position as a leading company in the pharmaceutical industry. Fagron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fagron stock

Intangible Assets of Fagron is 99.67 M EUR in 2025.

Intangible Assets of Fagron changed from 61.40 M EUR to 99.67 M EUR, representing a 62.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Fagron since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Fagron historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fagron

All Key Metrics — Fagron